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Abstract 
Although fibrosis is becoming increasingly recognized as a major cause of morbidity and 
mortality in modern societies, targeted anti-fibrotic therapies are still not approved for most 
fibrotic disorders. However, intense research over the last decade has improved our 
understanding of the underlying pathogenesis of fibrotic diseases. We now appreciate fibrosis 
as the consequence of a persistent tissue repair responses, which, in contrast to normal wound 
healing, fails to be effectively terminated. Profibrotic mediators released from infiltrating 
leukocytes, activated endothelial cells and degranulated platelets may predominantly drive 
fibroblast activation and collagen release in early stages, whereas endogenous activation of 
fibroblasts due epigenetic modifications and biomechanical or physical factors such as 
stiffening of the extracellular matrix and hypoxia may play pivotal role for disease 
progression in later stages. In the present review, we discuss novel insights into the 
pathogenesis of fibrotic diseases using systemic sclerosis (SSc) as example for an idiopathic, 
multisystem disorder. We set a strong translational focus and predominantly discuss 
approaches with very high potential for rapid transfer from bench-to-bedside. We highlight 
the molecular basis for ongoing clinical trials in SSc and also provide an outlook on upcoming 
trials. 
 
 
 
 
 
 
Page 2 of 29
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
3 
 
Introduction 
Fibrosis is defined as excessive deposition of fibrous connective tissue in an organ or tissue 
initiated by tissue repair programs in response to injury. The accumulation of extracellular 
matrix (ECM) often disrupts the physiological architecture, and can lead to organ 
malfunction. Normal wound healing and fibrotic diseases share many similarities. In both 
cases, an initial injury initiates a series of reparative processes in damaged tissues to restore 
organ integrity. These processes involve leukocyte activation and infiltration and culminate in 
the accumulation of myofibroblasts, which release ECM and contract the damaged tissue 
(Figure 1). Myofibroblasts are a heterogeneous cell population, characterized by the 
expression of contractile proteins and high capacity for ECM synthesis. Myofibroblasts may 
be primarily derived from transdifferentiation of resident fibroblasts and pericytes, but other 
tissue resident cell types such as epithelial cells, endothelial cells, smooth muscle cells, 
adipocytes as well as bone-marrow-derived fibrocytes and other precursor and progenitor cell 
populations may also contribute to the pool of myofibroblasts (Figure 1). However, while 
normal reparative responses are terminated after sufficient repair of damage, tissue 
remodeling and fibroblast activation persist in fibrotic diseases. Fibrotic diseases may thus be 
considered as exaggerated and prolonged wound healing responses (1). In consequence, 
impaired termination may also drive the progression of fibrotic diseases in addition to 
pathological activation of tissue repair responses (Figure 1).  
Fibrotic diseases can affect virtually every organ system. In addition to classic fibrotic 
diseases, tissue fibrosis is a common outcome of almost all chronic diseases. Fibrotic tissue 
responses can make an important contribution to morbidity or disease progression, even in 
diseases not commonly associated with fibrosis. For example, fibrotic tissue responses 
mediate vascular remodeling in atherosclerosis, myocardial remodeling in chronic heart 
failure, and small-airway remodeling in chronic obstructive pulmonary disease or in asthma. 
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Fibrotic tissue remodeling also influences tumor invasion and metastasis. Indeed, up to 45% 
of all deaths in the developed world have been estimated to be attributed to some type of 
chronic fibroproliferative disease (2). In general, the global incidence of fibrosis as well as the 
associated health-care burden are further increasing and therefore, fibrosis is increasingly 
recognized as one of today´s major healthcare challenges (2, 3). As there are only few 
antifibrotic therapies and even fewer targeted approaches, there remains a major need for 
continued intensive research and active drug discovery. 
Contrary to the held perception that fibrosis is permanent, multiple lines of evidence point to 
considerable plasticity of fibrotic tissues. Although this plasticity varies between different 
organs and individual diseases, the accumulation of extracellular matrix is not irreversible, but 
can regress, when major effector cells such as myofibroblasts are eliminated and the balance 
of matrix synthesis and degradation is shifted towards degradation (3). 
While originally pursued as different diseases, it is now clear that several common pathways 
orchestrate fibrotic tissue responses of all organs (4). This perception together with the 
identification and characterization of several key regulators of fibrosis stimulated increasing 
interest of pharmaceutical companies in the development of targeted antifibrotic therapies. 
Those efforts lead to the approval of the first two antifibrotic drugs (nintedanib and 
pirfenidone, both for idiopathic pulmonary fibrosis), a rapidly growing number of clinical 
trials with antifibrotic drugs and numerous promising small molecules in the earlier stages of 
clinical development. The most advanced approaches in the context of systemic sclerosis 
(SSc) are reviewed here. 
 
 
Vascular damage and platelet degranulation 
Vascular alterations in fibrotic diseases are particularly prominent in SSc and are associated 
with profound imbalances between pro- and anti-angiogenic mediators as well 
Page 4 of 29
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
5 
 
vasoconstrictive and vasodilatory factors. First vascular changes occur early in the 
pathogenesis of SSc and precede fibrotic manifestations in humans and in murine models (5). 
The exposure of sub-endothelial ECM and the reduced blood flow rates in damaged vessels 
lead to activation and degranulation of platelets in SSc (6). Platelet granules contain large 
amounts of serotonin (5-hydroxytrytophan, 5-HT). More than 90% of the serotonin in the 
human body is stored in platelets. Consistent with the increased activation of platelets in SSc, 
the levels of 5-HT are elevated in the blood of SSc patients. Inhibition of platelet activation by 
high doses of clopidogrel ameliorates fibrosis induced by bleomycin and in tight-skin-1 (Tsk-
1) mice (7). Anti-platelet therapy has also been shown to ameliorate fibrosis of the heart, the 
aortic valve, kidneys and liver (8, 9). Further studies demonstrated that mice deficient in 
tryptophan hydroxylase 1 (Tph-1), which are characterized by very low levels of 5-HT in 
platelets, are also protected from experimental fibrosis (7). 5-HT directly stimulates the 
release of collagen in cultured human fibroblasts, human mesangial cells or murine cardiac 
fibroblast. Pharmacologic and genetic approaches demonstrate that these stimulatory effects 
on fibroblasts are mediated by the 5-HTR2B. 5-HTR2B deficient mice are protected from 
experimental skin fibrosis (7). Treatment with the non-selective 5-HTR2 inhibitors terguride 
and cyproheptadine, both of which are in clinical use, as well as the selective 5-HTR2B 
inhibitor SB204741 also exerted potent anti-fibrotic effects. Selective inhibition of 5-HTR2B 
also showed therapeutic potential in mouse models of liver fibrosis (10).  
The effects of terguride in SSc patients were evaluated in a small, unblinded proof-of-concept 
trial. SSc patients treated with terguride were found to have lower modified Rodnan Skin 
Scores (mRSS) as compared to untreated controls. Moreover, the dermal thickness, 
myofibroblasts counts, the mRNA levels of type I collagen, of TGF-β1 and of the recently 
proposed four gene biomarker set (11) were reduced by treatment with terguride (12). These 
results prompted the initiation of randomized, placebo-controlled confirmatory phase III 
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clinical trial with terguride in patients with early, diffuse cutaneous SSc, which will start 
recruitment in autumn 2016.  
5-HT is not the only pro-fibrotic mediator stored in platelets. Platelet granules contain an 
array of other pro-fibrotic mediators including growth factors such as transforming growth 
factor-beta (TGF-β), platelet-derived growth factor (PDGF), fibroblast growth factors (FGF) 
and vascular endothelial growth factor (VEGF) and bioactive lipids such as lysophosphatidic 
acid (LPA) and sphingosine-1-phosphate (S1P) (13). Several of those mediators such and 
ongoing clinical programs to target those mediators are discussed in more detail below. The 
release of a plethora of profibrotic mediators from activated platelets at sites of vascular 
damage thus provides a direct pathophysiologic link between vascular injury and tissue 
fibrosis. 
Activation of the coagulation cascade upon tissue injury may also promote fibrosis in SSc as 
well as in other fibrotic diseases such as IPF (14). Thrombin enhances the proliferative effects 
of fibrinogen on fibroblasts, induces the expression of profibrotic growth factors, stimulates 
the release of extracellular matrix proteins and promotes transdifferentiation of resting 
fibroblasts into myofibroblasts. Thrombin levels are elevated in patients with SSc, and 
findings suggest that patients are in a hypercoagulable state (15). Direct thrombin inhibitors 
such as dabigatran reduce the activated phenotype of SSc fibroblasts and demonstrated 
antifibrotic effects model of bleomycin-induced lung fibrosis in the both preventive and 
therapeutic settings (16). Further, thromboxane A2 and its receptor (TXAR) have also been 
implicated in impaired angiogenesis in SSc. Patients have elevated circulating levels of 8-
isoprostane which activates TXAR (17) and increased expression of thromboxane synthase in 
leukocytes that results in increased serum levels of thromboxane A2 (18). Anticoagulation has 
been controversial in SSc-associated PAH and does not seem to offer a benefit advantage over 
other available PAH therapies (19). 
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Leukocyte activation and cytokine release  
A characteristic feature of SSc is the presence of perivascular inflammatory infiltrates 
associated with regions of activated fibroblasts and matrix remodeling. Inflammatory 
infiltrates are seen early in the course of SSc (5). These inflammatory infiltrates are thought to 
induce fibroblast activation and to initiate tissue repair responses in SSc. While research 
initially focused mainly on adaptive immune responses, accumulating evidence points to a 
key-role of innate immune responses in fibrotic diseases such as SSc and toll-like receptors as 
well as innate lymphocyte cells have gained increasing interest (20, 21). The central role of 
aberrant immune activation for fibrosis in SSc is particularly highlighted by the success of 
high dose immunosuppression with subsequent autologous stem cell transplantation (22). 
Although a plethora of inflammatory mediators might have the potential for targeted 
intervention, we focus here on candidates with ongoing clinical trial programs. Further 
potential targets are briefly highlighted in the Supplementary Table 1. 
 
Interleukin-6 (IL-6) is a central regulator of acute phase responses and also plays a key role 
for the transition from innate to acquired immunity. IL-6 signals are transduced into the 
nucleus by IL-6 receptor alpha (IL-6Rα) and gp130 via JAK/STAT (23). Among its 
pleiotropic effects, IL-6 has been implicated in fibroblast activation and collagen release. 
Serum levels of IL-6 are elevated in SSc patients and positively correlate with skin thickness 
(24). Increased amounts of IL-6 are also detected in lesional skin of SSc patients (25). 
Although IL-6Rα is not expressed on the surface of dermal fibroblasts, gp130 is expressed 
and IL-6 activates fibroblasts via trans-signaling through an association between soluble IL-6 
receptor, IL-6 and gp130 (26). Genetic deletion of the IL-6 gene in mice or treatment with 
anti-mouse IL-6 receptor antibodies attenuates bleomycin-induced fibrosis (27). A phase 2, 
randomized, placebo-controlled, double-blind trial of subcutaneous tocilizumab in patients 
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with early diffuse SSc and enriched for patients with inflammatory features, failed to meet its 
primary endpoint, but showed a clear trend towards improvement in the mRSS score. 
Moreover, several secondary and exploratory endpoints improved in a statistically significant 
manner (28, 29). Those results promoted a phase III, follow-up trial of tocilizumab in SSc, 
which is currently recruiting participants (NCT02453256).   
A central paradigm of fibrotic diseases is a Th2 bias in T cell differentiation. High levels of T 
helper (Th)2 cytokines such as IL-4 and IL-13 are reported in serum of SSc patients (30). IL-
13 targeting therapies attenuates experimental pulmonary and hepatic fibrosis (31, 32). 
However, a phase II double-blind, placebo-controlled trial of an anti-IL-13 antibody 
(QAX576, Novartis, Switzerland) in patients with IPF was closed preterm in 2013. Other 
approaches to target Th2 differentiation or cytokines are still at the level of preclinical or 
earlier clinical development (see supplementary table 1).  
B cells are part of the inflammatory infiltrates of fibrotic skin and the presence of 
autoantibodies in sera of patients with fibrotic diseases suggest that B cells are involved in the 
pathogenesis of fibrosis (33, 34). Chronically abnormal B cell activity might contribute to an 
imbalance of cytokines, which promotes Th2-predominance and fibrosis. In addition, certain 
autoantibodies e.g. against PDGF- (35), endothelin- and angiotensin-receptors (36) might 
directly stimulate the release of collagen from fibroblasts. The role of B cells in the 
pathogenesis of SSc is further supported by studies demonstrating the mice deficient in CD19 
are protected from fibrosis in the Tsk-1 mice as well as in bleomycin-induced fibrosis (37). A 
retrospective analyses within the EUSTAR cohort reported greater improvement of the mRSS 
and better forced vital capacity (FVC) in SSc patients treated with the B cell depleting CD20 
antibody rituximab as compared to controls (38). Prospective randomized-controlled trials are 
needed to confirm these encouraging results. Two trials with rituximab in SSc are currently 
ongoing: A phase II randomized, double blind, placebo controlled trial recruiting patients with 
SSc-PAH (NCT01086540) and a trial with SSc-associated arthritis (NCT01748084).  
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Another approach to target inflammation in SSc that is currently evaluated in a clinical trial is 
inhibition of the cannabinoid receptor CB2. Exogenous as well as endogenous cannabinoids 
transmit their signals by two different cell surface receptors, CB1 and CB2, both of which are 
heterotrimeric GTP binding protein coupled receptors. Cannabinoids can modulate fibrotic 
tissue responses via CB1 and CB2: While CB2 mainly regulates leukocyte infiltration, CB1 
may also affect resident cells such as fibroblasts (39, 40). Besides skin fibrosis, cannabinoids 
also contribute to the pathogenesis of liver fibrosis (41). Potential therapeutic effects of 
targeting CB2 with the synthetic cannabinoid-mimetic resunab in SSc are currently 
investigated in a phase II clinical trial in patients with early, diffuse-cutaneous SSc 
NCT02465437. 
 
 
Transforming growth factor-β signaling 
TGF-β is a master-regulator of mesenchymal tissue responses. Although TGF-β1 is the most 
abundantly expressed isoform, the other isoforms of TGF-β, TGF-β2 and TGF-β3, are also 
upregulated in SSc. In addition to its regulation on the transcriptional level, the availability of 
bioactive TGF-β is also modulated by cleavage of latent TGF-β and by sequestration in the 
extracellular matrix (for more details on TGF-β signaling in SSc, we refer to recent reviews 
such as (42)). Activation of TGF-β signaling, e.g. by fibroblast-specific overexpression of a 
constitutively active TGF-β receptor type 1 (TBRI
CA
), is sufficient to induce fibrosis (43). The 
expression of a subset of TGF-β regulated genes correlates with the mRSS and with 
myofibroblast counts (11). Numerous preclinical studies further demonstrated that inhibition 
of TGF-β signaling exerts potent anti-fibrotic effects in various animal models across 
different organs (42). Nevertheless, the first attempt to inhibit TGF-β signaling in SSc using 
recombinant TGF-β1-neutralizing antibodies (CAT-192) failed to show efficacy in a placebo-
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controlled trial (44). The results of this trial, however, do not provide evidence against 
inhibition of TGF-β signaling in SSc, because CAT-192 had only insufficient affinity to TGF-
β1 in vivo. A more recent uncontrolled study evaluated the effect of a high-affinity 
neutralizing antibody that targets all three TGF-β isoforms (fresolimumab) in SSc. The 
authors reported a decrease in the mRSS early after the first infusion of fresolimumab. This 
decrease was accompanied by reduced mRNA levels of several TGF-β-regulated genes and 
decreased myofibroblast counts in fibrotic skin (45). However, some studies noted a high 
number of keratoacanthomas at multiple sites in patients treated with fresolimumab (46). 
Mechanistically, the appearance of keratoacanthomas can be explained by the fact that TGF-β 
inhibits the proliferation of keratinocytes. While potent, systemic long-term inhibition of all 
TGF-β isoforms or direct targeting of the TGF-β receptors may thus be prohibited by safety 
concerns, several strategies have been developed to target downstream mediators of TGF-β 
signaling. 
A recently identified intracellular downstream mediator of TGF-β signaling with translational 
potential is the soluble guanylate cyclase (sGC). sGC catalyzes the production of cyclic 
guanosine monophosphate (cGMP) upon binding of nitric oxide (NO). Increasing levels of 
cGMP inhibit TGF-β dependent fibroblast activation (47). sGC stimulators do not interfere 
with canonical TGF-β signaling, but may exert their anti-fibrotic effects by inhibiting TGF-β 
dependent activation of Erk (48). sGC stimulators demonstrated antifibrotic effects in various 
experimental mouse models of SSc (47, 49). The sGC stimulator riociguat has been approved 
in 2015 for the treatment of pulmonary arterial hypertension. Riociguat is currently evaluated 
in a large randomized, placebo-controlled study in patients with early, diffuse cutaneous SSc.  
Nuclear receptors compose a superfamily of transcriptional regulators that are increasingly 
recognized as regulators of mesenchymal tissue responses. Several nuclear receptors have 
recently been suggested to be potential targets for anti-fibrotic therapies (50-54). Most 
advanced are clinical programs with agonists of peroxisome proliferator-activated receptors 
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(PPARs). In particular PPAR-γ has been linked to fibroblast activation in SSc. The expression 
of PPAR-γ is decreased in fibrotic tissues of SSc (55). PPAR-γ agonists such 
thiazolidinediones inhibit TGF-β-induced myofibroblast differentiation and collagen release 
in vitro by interfering with the recruitment of the coactivator p300 to Smad binding sites (56). 
Thiazolidinediones also ameliorate bleomycin-induced skin fibrosis. However, selective 
PPAR-γ agonists have been associated with elevated LDL levels and rosiglitazone was 
suspended from allowed use in Europe due to an increased risk of heart attack and stroke. 
Combined activation of all members of the PPAR family may overcome the safety limitations 
of thiazolidinediones. The pan-PPAR agonist IVA337 did not increase the levels of LDL and 
also demonstrated potent anti-fibrotic effects in several preclinical models of SSc (57). A 
randomized, controlled phase II trial with IVA337 in diffuse-cutaneous SSc has been started 
in October 2015.  
Vitamin D receptor (VDR) also regulates fibrotic tissue responses and has potential for rapid 
transfer from bench-to-bedside. Decreased levels of vitamin D have been observed in various 
autoimmune diseases including SSc (58). In addition to a lack of vitamin D, the expression of 
VDR is downregulated in SSc skin (51). VDR directly regulates the sensitivity of fibroblasts 
to the profibrotic effects of TGF-β: While knockdown of VDR enhanced TGF-β-induced 
myofibroblast differentiation and collagen release, synthetic VDR agonists reduced the 
stimulatory effects of TGF-β. Mechanistically, VDR binds to phosphorylated Smad3 to 
inhibit its transcriptional activation. Preventive and therapeutic treatment with VDR agonists 
ameliorated bleomycin- as well as TBRI
CA
-induced fibrosis. Moreover, VDR null mice 
spontaneously develop liver and vitamin D analogs prevent carbon tetrachloride (CCl4)-
induced liver fibrosis and renal fibrosis induced by unilateral ureteral obstruction (UUO) (59, 
60). Numerous compounds that modulate VDR signaling are currently in clinical use and 
would be available for clinical trials. 
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Bioactive lipid mediators such as lysophosphatidic acid (LPA) and shingosine-1-phosphate 
have also been identified as important regulators of TGF-β signaling in fibrotic diseases (61, 
62). The levels of LPA are elevated in the serum of SSc patients (63). LPA is chemotactic for 
fibroblasts, induces the expression of TGF-β and CTGF and promotes myofibroblast 
differentiation. Knockout of the lysophosphatidic acid-1 receptor (LPA-1) or treatment with 
antagonist of LPA1 protected from bleomycin-induced pulmonary and dermal fibrosis and 
ameliorated fibrosis in Tsk-1 mice (64). An orally available LPA1 receptor antagonist 
(SAR100842) was evaluated in a phase 2a clinical trial in patients with diffuse cutaneous SSc. 
Although no significant differences in the mRSS were observed between SAR100842 and 
placebo, effective target engagement was demonstrated and the levels of two potential 
biomarkers of skin fibrosis, COMP and TSP1, were reduced (65). Clinical trials with LPA 
antagonists (either LPA1 or LPA1-3) in SSc and in other fibrotic diseases are currently under 
consideration.  
Pirfenidone is approved for IPF based on reduced loss of FVC in two out of three trials as 
compared to placebo-treated patients. Although the molecular mechanisms underlying the 
antifibrotic effects of pirfenidone are incompletely understood, it is thought to work 
predominantly by modulating TGF-β and TNFα signaling. An open label phase II trial with 
pirfenidone in SSc-ILD has recently been completed (66). Although exploratory disease 
outcomes remained largely unchanged, a follow-up trial in patients with SSc-ILD is planned 
[NCT01933334]. 
Reactive oxygen species (ROS) produced by the NADPH oxidase (Nox) system are believe to 
play important roles in tissue injury and fibrosis (67). Several Nox isoforms have been 
identified with Nox2 and Nox4 being elevated in SSc and the most relevant to fibrosis (68) 
Inhibiting NOX4 by targeting using a small molecule (GKT137831) or deficiency of Nox4 
has been shown to reduce fibroblast activation in lung and liver (69, 70). The selective Nox 
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inhibitor, GKT137831 has completed safety trials [NCT02010242] and has recently been 
given orphan drug designation for development as a treatment in SSc.  
  
Integrins, mechanical forces and extracellular matrix  
The composition of the ECM, mechanical forces and ECM stiffness alter the activation and 
the bioavailability of several growth factors including TGF-β (71). Enhanced activation of 
latent TGF-β is thought to contribute to aberrant TGF-β signaling in fibrotic diseases. Several 
members of the integrin family of transmembrane receptors may contribute to enhanced 
activation of latent TGF-β in SSc. Alpha-V (αV) integrins are recognized as potent activators 
of TGF-β1 and TGF-β3. Deletion of Itgb6, which encodes integrin αVβ6 and is upregulated in 
SSc-associated ILD, leads to resistance to bleomycin-induced pulmonary fibrosis (42, 72). 
Integrin αVβ8 may also play important roles in TGF-β activation and fibrotic tissue 
remodeling (73). Furthermore, ECM proteins such as fibronectin and thrombospondin-1 can 
activate latent TGF-β.  
Fibroblasts do not only synthesize and remodel the ECM, but the composition and the 
mechanical properties of the ECM in turn influence fibroblast activation. Fibroblasts sense the 
stiffness of the ECM via integrins (74). β1 integrin is overexpressed on SSc fibroblasts. Mice 
with fibroblast-specific loss of β1 integrin are protected from bleomycin-induced fibrosis (75). 
Moreover, treatment with blocking antibodies against β1 integrin ameliorated fibrosis in a 
transgenic mouse model harboring a mutation in the fibrillin gene associated with stiff skin 
syndrome (76). These findings stimulated the initiation of clinical trials with blocking β1 
integrin antibodies in IPF and other indications such as SSc are currently under consideration. 
Besides targeting individual integrin subunits, inhibitors targeting selective heterodimers 
might be a promising and more specific approach as recently shown with a small molecule 
αvβ1 inhibitor (77). 
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The fibrils of collagen are crosslinked during collagen maturation to enhance their stability. 
The crosslinking of type I collagens is mediated by lysyl oxidase and lysyl oxidase-like 
(LOXL) 1-4, which are overexpressed in SSc and in other fibrotic diseases (78). Targeting 
LOXL2 with inhibitory antibodies reduced TGF-β signaling, inhibited collagen release and 
ameliorated experimental liver and lung fibrosis models (79). Although we are not aware of 
clinical trials in SSc, a humanized monoclonal anti-LOXL-2 antibody (GS-6624) is currently 
in phase II clinical trials for IPF and hepatic fibrosis.  
Several extracellular proteins are cleaved to release fragments, known as matrikines that exert 
biological activity. The non-collagenous carboxy terminal domain of collagen XVIII is 
cleaved by cathepsin L to release endostatin, a protein known for its anti-angiogenic activity 
(80). More recently, the anti-fibrotic activity of endostatin has emerged as one of its important 
functions. A peptide corresponding to the carboxy terminal region of endostatin was shown to 
exert anti-fibrotic activity in multiple pre-clinical models of skin and lung fibrosis (81). The 
mechanism of action of the peptide included reduction in the levels of the transcription factor, 
Egr-1, as well as reduction in extracellular matrix components and the cross-linking enzyme 
lysyl oxidase (82). Recombinant endostatin was shown to attenuate hepatic fibrosis induced 
by CCl4, to improve interstitial fibrosis in a mouse model of renal injury, to reduce 
bleomycin-induced lung fibrosis and inhibited hypertrophic scarring (83-85). It is worth 
noting that conflicting data are reported for in a myocardial infarction model (86).  
 
Stem cell pathways 
Accumulating evidence demonstrates that morphogenic pathways including Wnt, Hedgehog, 
Notch and Hippo signaling also play important roles in fibrotic diseases. 
The preclinical evidence for targeting Wnt, Hedgehog and Notch recently been reviewed in 
detail elsewhere (87-89). These studies may have direct translational implications as all 
pathways are drugable with several inhibitors either being either in advanced clinical 
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development or in already in clinical use (see supplementary table 1). While targeting of 
Notch signaling by inhibition of the γ-secretase complex maybe limited by gastrointestinal 
toxicity caused by a shift in differentiation from enterocytes in the intestinal crypts to muco-
secreting goblet cells (90), first clinical trials suggest that targeting of canonical Wnt signaling 
with tankyrase- and porcupine inhibitors is better tolerated. Targeting of hedgehog signaling 
with inhibitors of smoothened also showed a favorable adverse event profile and vismodegib 
is already approved for the treatment of basal cell carcinoma. However, despite those 
encouraging results, potential toxicity to the stem cell compartment of inhibitors of hedgehog, 
Notch and i.p. Wnt signaling remains a major safety concern for long-term application. A 
potential approach to overcome safety concerns with systemic application is topical 
application. This approach is currently investigated for C-82, a small molecule that interferes 
with the interaction of β-catenin with the coactivator CBP (NCT02349009).   
 
 
Epigenetics 
Epigenetics refers to all heritable changes in phenotype or in gene expression states, which are 
not encoded by changes of the nucleotide sequence of the DNA. Epigenetic modifications are 
thought to contribute to the basic activation of SSc fibroblasts under cell culture conditions 
and may contribute to the persistent tissue repair responses in fibrotic diseases. Several 
aberrant epigenetic modifications have been implicated in the pathogenesis of SSc and other 
fibrotic diseases (91-93).  
The most extensively studied target of aberrant DNA methylation in SSc is the Friend 
leukemia integration 1 (FLI1), a member of the ETS family of transcription factors. FLI1 is 
silenced due to increased promoter methylation in SSc fibroblasts (94). Knockdown of FLI1 
in cultured fibroblasts stimulates the release of collagen. Moreover, targeted heterozygous 
Page 15 of 29
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
16 
 
inactivation of Fli1 together with KLF5, another transcription factor epigenetically suppressed 
in SSc dermal fibroblasts, in mice (Fli1
+/-
;Klf5
+/-
 mice) reproduced the three cardinal 
pathological features of SSc, including immune abnormalities, vasculopathy, and fibrosis 
(95). Other genes downregulated by DNA methylation are suppressor of cytokine signaling 3 
(SOCS3) and endogenous Wnt antagonists such as dickkopf-1 (DKK1) and secreted frizzled-
related protein 1 (SFRP1) (96). Pharmacological inhibition of DNA methylation by 5-Aza-2′-
deoxycytidine normalized the expression levels of those antifibrotic genes inhibited the 
collagen release by SSc fibroblasts and ameliorated fibrosis in several mouse models of SSc 
(96). Moreover, inhibitors of Dnmts also demonstrated antifibrotic effects in murine models 
of other fibrotic diseases (97).  
 
 
Polypharmacologic approaches 
Polypharmacology describes the simultaneous inhibition of several pathologically relevant 
targets by a single drug. Given the complex pathogenesis of fibrotic diseases, a single 
pathway intervention is unlikely to be curative and polypharmacological interventions are 
considered as promising antifibrotic approaches despite the theoretically increased risk of 
adverse effects. The most relevant example to date is the multi-tyrosine kinase inhibitor 
nintedanib. Nintedanib has been shown in two phase 3 replication trials (INPULSIS-1 and -2) 
to slow the loss of FVC in patients with IPF and was approved for the treatment of IPF in 
2014/2015. Nintedanib blocks PDGFR α/β, fibroblast growth factor receptor (FGFR)-1, 2, 3, 
VEGFR-1, 2, 3 and the SRC-family kinases SRC, LYN and LCK by blocking the intracellular 
ATP-binding pocket (98). Several of the molecular targets of nintedanib such as PDGF-, 
VEGF- and SRC-signaling cascades have also been linked to the pathogenesis of fibrosis in 
SSc (99-103). Pathologic activation of PDGFRs and VEGFRs are both sufficient to induce 
fibrosis in mice (101, 102) and Src kinases serve as downstream mediators of several 
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profibrotic growth factors including TGF-β (103). Nintedanib thus offers an option for 
combined inhibition of several profibrotic pathways. Indeed, nintedanib inhibited 
proliferation, migration, myofibroblast differentiation and collagen release from cultured 
fibroblasts and showed anti-fibrotic effects in various in vivo models of SSc (104). The 
efficacy of nintedanib in SSc-ILD is currently evaluated in a phase III clinical trial 
(NCT02597933). 
 
Summary and conclusion 
Identification of potential targets is the initial step in the development of antifibrotic therapies. 
Increasing the framework for understanding the pathogenesis of fibrotic diseases will provide 
further insights and offer opportunities to develop effective antifibrotic treatment strategies. 
Indeed, our understanding of the molecular pathogenesis of fibrotic diseases is increasing and 
the list of potential molecular targets for the treatment of fibrosis is growing (supplementary 
table 1 and Figure 2). Several of those studies have direct translational implications as the 
identified mediators can be targeted pharmacologically with available drugs. Indeed, some of 
these studies have already been transferred from bench to bedside with clinical trials in 
preparation or ongoing (Table 1). The diversity of the available strategies raises hope to start 
into a new era of disease specific treatment strategies for fibrotic diseases.  
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Drug Target(s) Target 
population 
Phase Clinical 
trial 
identifier 
Status 
Actemra IL6R Early 
inflammatory 
dcSSc 
III NCT02453
256 
recruiting 
Nintedanib PDGFRs, 
FGFRs, 
VEGFRs, Src 
kinases 
ILD-SSc III NCT02597
933 
recruiting 
IVA-337 PPARs Early dcSSc II NCT02503
644 
recruiting 
Riociguat sGC Early dcSSc II NCT02283
762 
recruiting 
Terguride 5-HTR2 Early dcSSc III -- preparation 
Rituximab CD20 / B cells SSc-PAH II NCT01086
540 
recruiting 
Rituximab CD20 / B cells SSc- arthritis II NCT01748
084 
recruiting 
IVIG Fc receptors? dcSSc II NCT01785
056 
recruiting 
Resunab CB2 Early dcSSc II NCT02465
437 
recruiting 
Rilonacept IL1 dcSSc I/II NCT01538 recruiting 
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719 
C-82 
(topical) 
β-
Catenin/CBP 
interaction 
Early dcSSc  
I/II 
 
NCT02349
009 
ongoing, not 
recruiting 
Table 1: Placebo-controlled, blinded clinical trials for the treatment of fibrosis in SSc 
that are currently ongoing or expected to start 2016.  
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Figure 1: Physiologic and pathologic tissue responses. 
 
Figure 2: Pathways and network targets for tissue fibrosis in SSc.  
The common events in tissue remodelling and excessive scarring leading to persistent fibrosis 
can be targeted at selective points in the fibrogenic process.  Damage and chronic 
inflammation encourage the recruitment of progenitor populations into lesional tissue and 
stimulate the differentiation of resident fibroblasts. Activated myofibroblast contribute to the 
production, deposition and modification of the extracellular matrix (ECM). Abnormal ECM 
composition and structure enhance cell-matrix interactions which in the context of 
inflammation and a pro-fibrotic environment impede scar resolution promoting tissue fibrosis 
and persistence culminating in compromised organ function. 
ALK5 - Activin receptor-like kinase 5, ATX – Autotaxin, β-catenin - Catenin beta -1, C 
proteinase- procollagen C-proteinase (aka bone morphogenetic protein 1), CCR2 - C-C 
chemokine receptor type 2, CCR5 - C-C chemokine receptor type 5, CXCR4 - C-X-
C chemokine receptor type 4, Integrin (αvβx) – RGD receptors (e.g. Vitronectin, Fibronectin 
receptor), Elastase - A class of serine protease, FAK- Focal adhesion kinase 
Lox - Lysyl oxidase, LoxL2- Lysyl oxidase like 2, P4H- Prolyl 4-hydroxylase, PAI - 
Plasminogen activator inhibitor-1, PAR- Protease-activated receptors, ROCK1/2 - Rho-
associated protein kinase, RXFP1 - Relaxin/Insulin-Like Family Peptide Receptor 1, S1PR - 
Sphingosine-1-phosphate receptor, TGM2 – Transglutaminase 2, TNK1 - Tankyrase 1, Wnt- 
Evolutionary conserved signal pathway. Wnt being derived via a fusion of the name from the 
drosophila wingless gene and vertebrate homolog name, integrated   
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